|
Sponsor
|
Study Name and Link
|
|
Akebia
|
A 36-Week, Single-Group, Open-Label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children with Hyperphosphatemia Related to Chronic Kidney Disease.
|
|
Akebia
|
A 24-Week, Open-Label, Single-Arm Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children with Iron Deficiency Anemia Associated with Non-Dialysis Dependent Chronic Kidney Disease.
|
|
Bayer
|
Bayer: A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and Proteinuria
|
|
Astra Zeneca
|
A Study in Children With Hyperkalaemia Between Birth and <18 Years of Age to Evaluate Doses of Sodium Zirconium Cyclosilicate (SZC) for Correction of Hyperkalaemia and Effectiveness of Same Dose to Maintain Normokalaemia.
|
|
Otsuka
|
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
|
|
Otsuka
|
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
|
|
Relypsa
|
Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD)
|
